Contributions
Abstract: P450
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - Environmental risk factors
Objectives: Describe and compare the relative composition in bacterial taxa and archaea of the gut microbiota between patients with multiple sclerosis (MS) untreated and treated with interferon β-1b compared with healthy controls, in terms of phyla and more frequent taxa.
Background: The gut microbiota plays an important role in the development of experimental autoimmune encephalomyelitis; however, its role in MS is not yet defined.
Design and methods: Single centre descriptive study. Participants included 30 MS patients (half of whom had been treated with interferon β-1b for at least 9 months) and 14 otherwise healthy controls. A metagenomic study of faecal microbiota was conducted in stool samples collected for all the participants.
Results: The most common phyla across all 3 study groups included Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria.
The differences relating to the abundance of Firmicutes, Actinobacteria, Proteobacteria and Lentisphaerae between patients, untreated and treated with interferon β-1b, and controls were found to be statistically significant.
Firmicutes, Actinobacteria and Lentisphaerae differed between untreated MS patients, who tend to rebalance their microbiota after treatment, and controls.
The differences between MS patients and controls regarding bacterial abundance for 12 different species, including Prevotella copri DSM 18205, were found to be statistically significant; following treatment with interferon β-1b, these bacteria tend to achieve similar levels to those found in healthy subjects.
Patients with MS showed lower abundance of Archaea than healthy controls.
Conclusions: Our findings suggest that the gut microbiota is significantly altered in patients suffering from MS compared to healthy subjects.
Interferon β-1b tends to be effective at rebalancing the gut microbiota of patients affected with this condition, being this particularly evident for Prevotella copri. DSM 18205
These preliminary results support the need for further studies on the potential role of microbial dysbiosis for preventing and treating MS.
Disclosure:
Federico Castillo-Álvarez: nothing to disclose
Patricia Pérez Matute: nothing to disclose
Sandra Colina Lizuain: nothing to disclose
Amaia Erdocia Goñi: nothing to disclose
Carmen Iglesias Gutiérrez Cecchini: nothing to disclose
Eugenia Marzo Sola: nothing to disclose
Abstract: P450
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - Environmental risk factors
Objectives: Describe and compare the relative composition in bacterial taxa and archaea of the gut microbiota between patients with multiple sclerosis (MS) untreated and treated with interferon β-1b compared with healthy controls, in terms of phyla and more frequent taxa.
Background: The gut microbiota plays an important role in the development of experimental autoimmune encephalomyelitis; however, its role in MS is not yet defined.
Design and methods: Single centre descriptive study. Participants included 30 MS patients (half of whom had been treated with interferon β-1b for at least 9 months) and 14 otherwise healthy controls. A metagenomic study of faecal microbiota was conducted in stool samples collected for all the participants.
Results: The most common phyla across all 3 study groups included Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria.
The differences relating to the abundance of Firmicutes, Actinobacteria, Proteobacteria and Lentisphaerae between patients, untreated and treated with interferon β-1b, and controls were found to be statistically significant.
Firmicutes, Actinobacteria and Lentisphaerae differed between untreated MS patients, who tend to rebalance their microbiota after treatment, and controls.
The differences between MS patients and controls regarding bacterial abundance for 12 different species, including Prevotella copri DSM 18205, were found to be statistically significant; following treatment with interferon β-1b, these bacteria tend to achieve similar levels to those found in healthy subjects.
Patients with MS showed lower abundance of Archaea than healthy controls.
Conclusions: Our findings suggest that the gut microbiota is significantly altered in patients suffering from MS compared to healthy subjects.
Interferon β-1b tends to be effective at rebalancing the gut microbiota of patients affected with this condition, being this particularly evident for Prevotella copri. DSM 18205
These preliminary results support the need for further studies on the potential role of microbial dysbiosis for preventing and treating MS.
Disclosure:
Federico Castillo-Álvarez: nothing to disclose
Patricia Pérez Matute: nothing to disclose
Sandra Colina Lizuain: nothing to disclose
Amaia Erdocia Goñi: nothing to disclose
Carmen Iglesias Gutiérrez Cecchini: nothing to disclose
Eugenia Marzo Sola: nothing to disclose